Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 462258838 | IUPAC_name = (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid | image = Nateglinide.svg | image_class = skin-invert-image
| tradename = Starlix | Drugs.com = | MedlinePlus = a699057 | licence_EU = yes | licence_US = Nateglinide | pregnancy_category = | legal_UK = POM | legal_US = Rx-only | legal_status = | routes_of_administration = Oral
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).